Abstract:Abstract Background VTX002 is a novel oral selective sphingosine-1-phosphate-1 (S1P1) receptor modulator in development for the treatment of ulcerative colitis (UC). The efficacy and safety of VTX002 in patients with ulcerative colitis (UC) was assessed in a phase 2, multicentre, randomised, double-blind, placebo-controlled study (NCT05156125). Methods Adults (N=213) with moderately to severely active UC (modified Mayo score [MMS] 4-9) and inadequate response/intolerance to conventional and/or advanced (approved biologics or Janus kinase inhibitor) therapies were randomised 1:1:1 to once daily treatment with placebo (n=70), 30 mg (n=73) or 60 mg (n=70) VTX002 tablets for 13 weeks. Patients underwent a 6–8-day dose titration up to the assigned treatment dose. The primary endpoint was clinical remission (MMS stool frequency subscore ≤ 1, rectal bleeding subscore=0, and endoscopic subscore [ES] ≤ 1) at week 13. A protocol amendment limiting eligibility to patients with baseline MMS 5-9 resulted in 213 and 209 patients in the safety and efficacy populations, respectively. Key secondary endpoints were endoscopic improvement, symptomatic remission, histologic remission, and endoscopic improvement-histologic remission. Endoscopic remission and histologic-endoscopic mucosal improvement (HEMI) were also assessed (see Table 1 for outcome definitions). Adverse events (AEs) and laboratory abnormalities were assessed for safety. Results The primary endpoint of clinical remission at week 13 was achieved (27.9% of patients who received VTX002 60 mg vs 11.4% of patients who received placebo, ∆=16.5%, p=0.0184). Both doses of VTX002 achieved nominal statistical significance for all key secondary endpoints (Table 1). Significantly greater proportions of patients who received VTX002 60 mg achieved endoscopic remission and HEMI compared to patients who received placebo (29.4% VTX002 60 mg vs 7.1% placebo, ∆=22.3%, p=0.0012, and 32.4% VTX002 60 mg vs 10.0% placebo, ∆=22.4%, p=0.0026, respectively). A dose-dependent decrease of 67.7% and 53.9% in mean absolute lymphocyte count (ALC) from baseline was observed at week 8 for patients who received VTX002 60 mg and 30 mg, respectively. Most AEs were mild to moderate (Table 2). No AEs of bradycardia, atrioventricular block, serious infections, macular oedema, or deaths were reported. Conclusion The S1P1 receptor modulator VTX002 was well-tolerated and statistically superior to placebo for induction of clinical, endoscopic, histologic, HEMI, and symptomatic remission/response at week 13. These positive findings, including a dose-dependent pharmacodynamic reduction in ALC, support phase 3 development of VTX002 for treatment of UC.

What problem does this paper attempt to address?

This paper aims to evaluate the efficacy and safety of the oral selective sphingosine - 1 - phosphate - 1 (S1P1) receptor modulator VTX002 in patients with moderate - to - severe active ulcerative colitis (UC). Specifically, through a multicenter, randomized, double - blind, placebo - controlled phase II clinical trial (NCT05156125), the study investigated the efficacy of VTX002 in improving patients' clinical symptoms, endoscopic examination results, histological indicators, etc., and evaluated its safety. ### Research Background VTX002 is a new oral selective S1P1 receptor modulator for the treatment of ulcerative colitis (UC). The main purpose of this study was to evaluate the efficacy and safety of VTX002 in UC patients. ### Research Methods The study included 213 adult patients with moderate - to - severe active UC (modified Mayo score [MMS] 4 - 9 points), who had a poor response or intolerance to conventional therapies and/or advanced therapies (such as approved biologics or Janus kinase inhibitors). Patients were randomly divided into three groups and received placebo (n = 70), VTX002 30 mg (n = 73), or VTX002 60 mg (n = 70) once daily for 13 weeks. Before starting treatment, patients required a 6 - 8 - day dose escalation to reach the specified treatment dose. The primary endpoint was to achieve clinical remission at week 13 (MMS fecal frequency sub - score ≤ 1, rectal bleeding sub - score = 0, endoscopic score [ES] ≤ 1). Key secondary endpoints included endoscopic improvement, symptom remission, histological remission, and endoscopic - histological remission (HEMI). ### Research Results - **Primary Endpoint**: At week 13, 27.9% of patients receiving VTX002 60 mg achieved clinical remission, while in the placebo group it was 11.4%, with a significant difference (Δ = 16.5%, p = 0.0184). - **Secondary Endpoints**: Both VTX002 dose groups achieved nominal statistical significance in all key secondary endpoints. - **Endoscopic Remission and HEMI**: 29.4% of patients receiving VTX002 60 mg achieved endoscopic remission, while in the placebo group it was 7.1% (Δ = 22.3%, p = 0.0012); 32.4% of patients achieved HEMI, while in the placebo group it was 10.0% (Δ = 22.4%, p = 0.0026). - **Pharmacodynamics**: In patients receiving VTX002 60 mg, the mean absolute lymphocyte count (ALC) decreased by 67.7% from the baseline level, while in patients receiving VTX002 30 mg it decreased by 53.9%. - **Safety**: Most adverse events (AEs) were mild to moderate, and no serious adverse events such as bradycardia, atrioventricular block, severe infection, macular edema, or death were reported. ### Conclusion As an S1P1 receptor modulator, VTX002 shows statistically significant advantages in inducing clinical, endoscopic, histological, HEMI, and symptom remission in UC patients and is well - tolerated. These positive results, including dose - dependent ALC reduction, support VTX002 to enter phase III clinical trials to further evaluate its potential in treating UC.

OP03 Efficacy and safety of the oral selective sphingosine-1-phosphate-1 receptor modulator VTX002 in moderately to severely active Ulcerative Colitis: results from a randomised, double-blind, placebo-controlled, phase 2 trial

DOP01 Efficacy and Safety of the IL-6 Trans-Signalling Inhibitor Olamkicept: a Phase 2 Randomized, Placebo-Controlled Trial in Moderately to Severely Active Ulcerative Colitis

P658 Safety and efficacy of MH002, an optimized live biotherapeutic product, for the treatment of mild to moderate ulcerative colitis: a first-in-disease, double-blind, randomized clinical trial

Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study

Efficacy and Safety of Sphingosine 1-Phosphate Receptor Modulators for Ulcerative Colitis

P572 Evaluation of safety, pharmacokinetics and efficacy of oral treatment with OST-122 in patients with moderate to severe ulcerative colitis: A Phase Ib/IIa, randomized, double blind, placebo controlled clinical trial

S744 QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients with Moderately to Severely Active Ulcerative Colitis

775C A Phase 2 Randomized Controlled Trial Demonstrating the Efficacy and Safety of Shr0302, A Selective JAK1 Inhibitor for the Treatment of Moderate to Severe Ulcerative Colitis Patients.

Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies

Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme

Efficacy and safety of the S1PR modulator etrasimod in the treatment of moderately to severely active ulcerative colitis during the induction phase: a systematic review and meta-analysis of randomized controlled trials

P033 Single-cell analysis of gut mucosal- and peripheral blood cells in ulcerative colitis patients undergoing vedolizumab treatment

P795 Efficacy and safety of etrasimod as a first-line advanced treatment following 5-aminosalicylic acid and/or thiopurines: Data from the ELEVATE UC 52 and ELEVATE UC 12 phase 3 clinical trials

EVALUATING THE PRE-CLINICAL EFFICACY OF VT1021 (A CLINICAL STAGE DRUG CANDIDATE) IN MULTIPLE EXPERIMENTAL MODELS OF INFLAMMATORY BOWEL DISEASE

Safety and efficacy of S1P receptor modulators for the induction and maintenance phases in inflammatory bowel disease: A systematic review and meta-analysis of randomized controlled trials

Effectiveness and safety of vedolizumab and infliximab in biologic‐naïve patients with moderate‐to‐severe ulcerative colitis: A multicenter, retrospective cohort study

Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis

P628 Vedolizumab in Indian patients with Inflammatory Bowel Disease: Interim results from a prospective, multicentre, open-label, phase 4 study

A NEW APPROACH FOR TREATMENT OF ULCERATIVE COLITIS: A MELANOCORTIN RECEPTOR AGONIST PL8177

Pentoxifylline in patients with ulcerative colitis treated with mesalamine by modulation of IL-6/STAT3, ZO-1, and S1P pathways: a randomized controlled double-blinded study